Compare GameStop Corp. (GME) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GameStop Corp. vs Eli Lilly And Co — how do they compare? GameStop Corp. trades at $26.56 (market cap $12.75B), while Eli Lilly And Co trades at $1,179.27 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 81.6× GameStop Corp.'s market cap, and Eli Lilly And Co pays a 0.59% dividend while GameStop Corp. pays none. Which is the better fit depends on your goals — on Pluang, investors hold GameStop Corp. for 62 Days and Eli Lilly And Co for 93 Days on average.
| GME | LLY | |
|---|---|---|
Market Cap | $12.75B | $1.04T |
Volume | 13,026,993 | 3,064,878 |
Sector | Consumer Cyclical | Health |
52-Week High | $26.53 | $1.28K |
52-Week Low | $17.87 | $799.57 |
Typical Hold Time | 62 Days | 93 Days |
Enterprise Value | $12.03B | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GME trades at $25.28, up 2.85% today, with a bullish technical signal and strong insider buying. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. The company's balance sheet is robust with $4.77 billion in cash and low debt, while profitability improved significantly with a net income margin of 3.43% in 2025.
Outlook remains positive due to strong cash reserves and insider confidence, but risks include revenue decline and competitive pressures. Analyst consensus is cautious with only 16.67% buy ratings. The stock's valuation metrics suggest moderate pricing relative to earnings and sales.
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
